Recent anecdotal and scientific reports have provided evidence of a link between COVID-19
and chemosensory impairments, such as anosmia. However, these reports have …

Background Meta-analyses on the effects of probiotics on specific gastrointestinal diseases
have generally shown positive effects on disease prevention and treatment; however, the …

In a preregistered, cross-sectional study, we investigated whether olfactory loss is a reliable
predictor of COVID-19 using a crowdsourced questionnaire in 23 languages to assess …

Importance Underrepresentation of many racial/ethnic groups in Alzheimer disease (AD)
clinical trials limits generalizability of results and hinders opportunities to examine potential …

Background Timely accrual of a representative sample is a key factor in whether Alzheimer’s
disease (AD) clinical trials successfully answer the scientific questions under study. Studies …

BackgroundCOVID-19 has heterogeneous manifestations, though one of the most common
symptoms is a sudden loss of smell (anosmia or hyposmia). We investigated whether …

Efforts to provide patients with individualized treatments have led to tremendous breakthroughs
in healthcare. However, a precision medicine approach alone will not offset the rapid …

The recent FDA approval of amyloid-lowering drugs is changing the landscape of Alzheimer
disease (AD) clinical practice. Previously, apolipoprotein E (APOE) genetic testing was not …

Background: Best approaches for retaining research participants in Alzheimer’s disease
cohort studies are understudied. Objective: Using data from the National Alzheimer’s …

Background Participant retention is a key factor that affects clinical trial integrity. Trial protocols
estimate attrition as a function of sample size calculations. Alzheimer’s disease (AD) is an …